Mucus Dehydration and Evolution of CF Lung Disease

粘液脱水和 CF 肺病的演变

基本信息

  • 批准号:
    7231813
  • 负责人:
  • 金额:
    $ 24.56万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-12-01 至 2011-07-31
  • 项目状态:
    已结题

项目摘要

Cystic fibrosis (CF) is the most common lethal genetic disease in the Caucasian population. The vast majority of these patients die from lung disease that is characterized by thick airway secretions, progressive airways obstruction, and chronic infection with characteristic bacterial pathogens. The natural history of CF includes both a gradual decline and acute episodic deteriorations (termed exacerbations). Abnormalities in salt and water transport across the airway epithelium have been shown to cause dehydration of the lining fluid that covers airway surfaces in vitro, and it is postulated that this defect leads to reduced mucus clearance in the CF lung. Our long-term goal is to determine the extent that airway secretion dehydration contributes to the evolution of CF lung disease, and to develop strategies that maintain mucus hydration and clearance beginning early in life. We will pursue this goal through the following specific aims: (1) Test the hypothesis that CF lung disease progression is associated with changes in mucus hydration; (2) Test the hypothesis that acute exacerbations result from triggering events (i.e. viruses) that provoke a regional collapse of mucus clearance; and (3) Test the hypothesis that hypertonic saline safely and effectively leads to a sustained increase in mucociliary clearance and reduces airway obstruction in children with CF. In the first aim, we will directly measure the hydration of airway secretions, regulators of mucus hydration (e.g. nucleotides, cytokines), and the consequences of mucus dehydration (e.g. mucus rheology; evolution of bacterial communities) across a wide spectrum of lung disease severity. In the second aim, we will prospectively study the effect that acute exacerbations have on mucociliary clearance in vivo using gamma scintigraphy; we will directly measure mucus properties that may alter mucus clearance (i.e. hydration) during an exacerbation; and we will determine the role that respiratory viruses have on triggering acute exacerbations using sensitive PCR techniques, in the third aim, we will determine whether hypertonic saline, by addressing this hydration defect, can lead to sustained improvements in mucociliary clearance and lung function in children (age 5-12 years) with CF, and whether this intervention is safe and well tolerated in infants (age <3 years) with CF. These studies will directly impact our understanding of mucus clearance in the progression and treatment of CF, and more generally its role in health and other airways diseases.
囊性纤维化(CF)是高加索人群中最常见的致死性遗传疾病。绝大

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SCOTT H DONALDSON其他文献

SCOTT H DONALDSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SCOTT H DONALDSON', 18)}}的其他基金

Project 3: Treatment of mucostasis and airways obstruction in CF with a novel mucolytic
项目 3:用新型粘液溶解剂治疗 CF 中的粘膜淤积和气道阻塞
  • 批准号:
    9356820
  • 财政年份:
    2017
  • 资助金额:
    $ 24.56万
  • 项目类别:
MUCUS CLEARANCE DURING ACUTE EXACERBATIONS OF CYSTIC FIBROSIS
囊性纤维化急性发作期间的粘液清除
  • 批准号:
    7716866
  • 财政年份:
    2008
  • 资助金额:
    $ 24.56万
  • 项目类别:
COMPREHENSIVE ANALYSIS OF MALNUTRITION IN ADULTS WITH CYSTIC FIBROSIS
成人囊性纤维化营养不良的综合分析
  • 批准号:
    7377447
  • 财政年份:
    2005
  • 资助金额:
    $ 24.56万
  • 项目类别:
EFFICACY OF AMILORIDE AND HYPERTONIC SALINE IN CYSTIC FIBROSIS
阿米洛利和高渗盐水治疗囊性纤维化的疗效
  • 批准号:
    7200178
  • 财政年份:
    2004
  • 资助金额:
    $ 24.56万
  • 项目类别:
COMPREHENSIVE ANALYSIS OF MALNUTRITION IN ADULTS WITH CYSTIC FIBROSIS
成人囊性纤维化营养不良的综合分析
  • 批准号:
    7200252
  • 财政年份:
    2004
  • 资助金额:
    $ 24.56万
  • 项目类别:
ORAL SPI-8811 IN PATIENTS WITH CYSTIC FIBROSIS
囊性纤维化患者口服 SPI-8811
  • 批准号:
    7200288
  • 财政年份:
    2004
  • 资助金额:
    $ 24.56万
  • 项目类别:
Efficacy of Amiloride and Hypertonic Saline in Cystic Fibrosis
阿米洛利和高渗盐水治疗囊性纤维化的疗效
  • 批准号:
    6980600
  • 财政年份:
    2003
  • 资助金额:
    $ 24.56万
  • 项目类别:
Comprehensive Analysis of Malnutrition in Adults with Cystic Fibrosis
成人囊性纤维化营养不良的综合分析
  • 批准号:
    6980693
  • 财政年份:
    2003
  • 资助金额:
    $ 24.56万
  • 项目类别:
Core E: Clinical Translation Core
核心 E:临床翻译核心
  • 批准号:
    10227489
  • 财政年份:
    2003
  • 资助金额:
    $ 24.56万
  • 项目类别:
Oral SPI-8811 in Patients with Cystic Fibrosis
囊性纤维化患者口服 SPI-8811
  • 批准号:
    6980723
  • 财政年份:
    2003
  • 资助金额:
    $ 24.56万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了